People · Operator
Named in public records as an officer, director or promoter · active 2024–2025 · Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | — | Pharmaceuticals | Series C | $192.5M | $612.3M | 2024 |
| ACKWEST Group, Inc. | — | Other Technology | Series B | $17.6M | $102.2M | 2025 |
Hugh Davis at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Hugh Davis on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Ketan Patel | 1 | 10 |
| Albert Cha | 1 | 9 |
| David Gordon | 1 | 8 |
| Stephen Tullman | 1 | 7 |
| ANAND MEHRA | 1 | 7 |
| Andrew Schiff | 1 | 5 |
| Neal Walker | 1 | 5 |
| John Almeida | 1 | 4 |
| Maxine Gowen | 1 | 4 |
| Christopher Powala | 1 | 3 |
| Andrew Powell | 1 | 3 |
| Joseph Monahan | 1 | 3 |
| Andrew A. Schiff | 1 | 3 |
| Kamil Ali-Jackson | 1 | 3 |
| William Humphries | 1 | 2 |
| Christopher Molineaux | 1 | 2 |
| Sanjay Swani | 1 | 2 |
| Joel Mesznik | 1 | 2 |
| Stephen A. Tullman | 1 | 2 |
| Keith Price | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.